1. Efficacy and Safety of Oral Chelators in Treatment of Patients With Wilson Disease 
Karl Heinz Weiss, Florentine Thurik, Daniel Nils Gotthardt, Mark Schäfer, Ulrike Teufel, Franziska Wiegand, Uta Merle, Daniela Ferenci– Foerster, Andreas Maieron, Rudolf Stauber, Heinz Zoller, Hartmut H. Schmidt, Ulrike Reuner, Harald Hefter, Jean Marc Trocello, Roderick H.J. Houwen, Peter Ferenci, Wolfgang Stremmel 
Clinical Gastroenterology and Hepatology 
Volume 11, Issue 8, Pages e2 (August 2013)
DOI: /j.cgh
Copyright © 2013 AGA Institute Terms and Conditions

2. Figure 1
Number of treatments in the study cohort. Hepatic and neurologic outcomes were scored for each treatment at defined time points (6, 12, 24, 36, and 48 mo) as follows: improved to normal, improved but not normal, unchanged, worsened, or asymptomatic over duration. Combination therapies (25 treatments with DPA and zinc; 21 treatments with trientine and zinc) were not included in the numbers provided in this flow chart and were not included in the statistical analysis.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions

3. Figure 2
Discontinuation of treatments for (A) any cause or because of (B) adverse events, analyzed by Kaplan–Meier estimation.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2013 AGA Institute Terms and Conditions